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Using monoclonal antibodies, recombinant human ')I-in-
terferon, and fluorescence-activated cell sorter, 2 human 
melanoma celI lines (KHm-1/4 and A101D) were examined 
quantitatively for HLA-DR and 97-kD melanoma-associ-
ated antigen (p97) expression throughout the cell cycle. 
Two-color flow cytom etric analysis showed that the mean 
cell volume increased (KHm-1I4, 2.6 times; A101D, 3.6 
times) during the progression of the cell cycle, and that 
fluorescence intens ity of HLA-DR and p97 correlated well 
with cell volume, i. e., both antigens were maximally de-
tected during the GrM phase. The density of HLA-DR 
and p97 on the cell surface remained relatively constant 
throughout the cell cycle with the exception that cells in S 
phase showed a slightly lower density compared with those 
T he expression of HLA-DR on the cell surface is re-quired for various immune responses [1]. HLA-DR molecules were first discovered o n B Iymphoctyes and monocytes [2], but they can also be expressed by various normal cells [3-6] and various tumor cells [7], 
including malignant melanoma [8,9]. Primary HLA-DR + cells 
are reported to activate the proliferation and cytotoxicity of au-
tologous lymphocytes [10] . On the other hand , mice immunized 
with tumor-associated transplantation antigens could resist chal-
lenge with transplanted melanoma cells [11]. Those reports sug-
gest the potential roles of HLA-DR and melanoma-associated 
antigens (MAA) in regulating antitumor host reactions in patients 
w ith m aligna nt melanoma. y-Interferon has been shown to induce 
HLA-DR expression in a w ide variety of cell types [1 2-17] in-
cluding melanoma cells [17-19] and to increase the expression of 
MAA in human melanoma cell lines (1 9). On the other hand , 
Manuscript received December 11, 1985; accepted for publication March 
17, 1986. 
Reprint requests to: Koichiro Kameyama, M.D., Laboratory of Cell 
Biology, Bui lding 37, Room lB27, National Institutes of Health , Be-
thesda, Maryland 20892. 
Abbreviations: 
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F1TC: flu orescein isothiocyanate 
MAA: melanoma-associated antigen 
PBS: phosphate-buffered sa line 
PI: propidium iodide 
in GoIG1 and G2-M phases. ')I-Interferon treatment (500 
IU/ml, 72 h) increased HLA-DR + cells (KHm-1/4, 65% 
to 89%; A101D, 34% to 84%) and p97+ cells (KHm-1/4, 
8% to 12%; A101D, 19% to 35%). Increased antigen den-
sities were also relatively constant throughout the cell cycle 
as in nontreated cells. Cells treated with ')I-interferon tended 
to accumulate at GoIG, phase (KHm-1I4, 21% to 37%; 
A101D, 17% to 53%), and had a reduced cell volume 
(0.82-0.95 times) throughout cell cycle. This study re-
vealed that both melanoma cell lines showed heterogeneity 
in the expression of HLA-DR and p97, and that this het-
erogeneity was influenced, at least in part, by cell cycle and 
immunologic events such as ')I-interferon treatment.] Inllest 
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some MAA expressions were reduced after t,eatment with 
y-interferon [20]. 
These HLA-DR and MAA were reported to be expressed het-
erogeneitically by some melanoma cells [21,22). The reason for 
this heterogeneity is not elucidated at the present time. However, 
cell surface antigens were reported to be related to the cell cycle 
in melanoma [23,24] and in other tumors [25-29]. The aims of 
this study are: (1) to quantitate the level of HLA-DR and MAA 
throughout the cell cycle; (2) to exa mine the effects of y-interferon 
on the expression ofHLA-DR and MAA; and (3) to examine the 
antiproliferative effects of y-interferon on human melanoma cell 
lines. In this study, we used p97 (30) as a model for MAA expres-
sion . This is the first study that has reported the antigen densities 
of HLA-DR and MAA throughout cell cycle on y-interferon-
treated melanoma cells. 
MATERIALS AND METHODS 
Interferon Recombinant human y-interferon from Escherichia 
coli was supplied by Japan Roche, Ltd. (Tokyo, Japan) . The titer 
of y-interferon determined by virus inhibition plaque assay was 
5-9 x 106 IU / mg. 
Cell Culture Two human melanoma cell lines (KHm-1/4 and 
AI01D) were used in this study. The origin and characteristics 
of these cells have been described [31-33]. The cells (1 x 105) 
were plated on 35-111111 dishes (Falcon Plastics Co., Oxnard, Cal-
ifornia) in Dulbecco's modified Eagle's medium (DMEM) sup-
plemented with 10% heat-inactivated fetal calf serum (FCS), 100 
J,Lg /ml streptomycin , and 100 U / ml penicillin . The cells were 
maintained at 37°C in a humidified in.cubator with 5% CO2 in 
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air. y-Interferon was added at 48 h after cell seedin g for all ex-
periments except the anti proliferative stud y. Cells used in ex-
periments were in their exponential phase of growth . 
Monoclonal Antibodies Antibodies used in this study were 
the anti-HLA-DR monoclonal antibody L243 and the anti-p97 
monoclonal antibody 96.5. The immunohistologic characteristics 
of these monoclonal antibodies have been described elsewhere 
[34,35]. 
Immunofluorescence Staining Melanoma cells (1 x 106) were 
rinsed twice with phosphate-buffered saline (PBS) and then treated 
with 20 J-LI containing 12.5 J-Lg 96.5 IgG, or 50 J-LI L243 culture 
supernatant for 30 min on ice. After washing tw ice with PBS , 
cells were treated wi th 20 J.tI of a 1: 10 dilution of fluorescein 
isothiocyanate (FITC)-conjugated goa t antimouse immunoglob-
ulin (Tago, Co ., Ltd., Burlingame, Californi a) for 30 min on ice. 
Then the cells were washed twice with PBS and finally suspended 
in PBS containing 0.02% sodium azide and analyzed with a flu-
orescence-activated cell sorter (FACS IV, Becton Dickinson Co., 
Ltd., Mountain View, California). Nonspecific and background 
staining were determined by omitting the first antibody. In de-
terminin g the percent of positive cells, a marker w as set on the 
negative con trol histogram such that 1 % of the cells were to the 
right of this channel marker. 
DNA Staining Modifi ed Krishan's meth od [36] was used in 
this study. Briefly, after immunofluorescence staining, 2 x 106 
cells were fixed in 70% ethanol for 30 min on ice. After washing 
PBS, cells were treated with 0.05 mg/ml propidium iodide (PI, 
Sigma) solution containin g 0.1 % sodium citrate for 20 min on 
ice. After washing and resuspension in PBS, the FITC/ PI-stained 
cells were analyzed with FACS. The 488-nmlaser beam was used 
to excite FITC inimunofluorescence as well as PI-DNA fluores-
cence in doubly stained samples. Immunofluorescence was de-
tected in the wavelength interval from 515 to 545 nm with pho-
tomultiplier tube 1, whereas DNA fluorescence from PI was 
detected at wavelengths > 610 nm with photomultiplier tube 2. 
Cell volume was detected by forw ard angle light scatter in all 
experiments. As each cell from the dual-stained sample passed 
through the laser beam , corrected measurements of forward light 
sca tter, FITC flu orescence, and PI flu orescence were collected. 
Cell subpopulations (Go/G), S, and G 2- M) are represented by the 
generated peaks which are scaled arbitrarily and are proportioned 
to cell number! channel. 
Calculation of Mean Surface Density of Antigens Analysis 
of the surface density of the antigens was perform ed as described 
previously [37]. The cell volume was ca librated aga inst 2 standard 
spherical beads (10 and 20 J-Lm in diameter; Epics Division of 
Coulter Corp . , Hialeah, Florida) and the frequency distribution 
was used to derive the mean volume for calculation of the cell 
surface area. T he specific immunofluorescence of each of the ga ted 
cells was expressed in relative fluo rescence units or channel num-
bers. T he mean fluorescence value of cell antigen content was 
divided by the mean cell surface area of the cell population at each 
cell cycle phase. 
Effect of l'-Interferon on Cell Growth The cells (1 X 104) 
were plated in 35-mm dishes in DMEM w ith 10% FCS; y-in-
terferon was added 24 h after cell seeding and fed every other day 
with fresh y-interferon containing culture medium. Cells were 
counted w ith a hemocytometer and each cell count determination 
represents the average of the means obtained on duplicate or 
triplicate dishes. T he total cell number per dish rep resents the 
cumulative sum of the number of attached and fl oating cells. 
RES ULTS 
Cell Volume, Surface Area, and DNA Contents of Mela-
noma Cells During Cell Cycle The mea n cell volume as well 
as the cel l surface area increased sharply between GO/G 1 and S, 
and between Sand G2-M on both cell lines. The cell volume of 
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Table I. Cell Volume and Cell Surface Area in Cell Cycle 
Cell Cycle Compartment 
Cell Line Gu/G, S G2-M 
KHm-l /4 1.1 2.1 2.9 
Cell volume (J-tm3 X 10 - 4) 
Cell surface area (J-tm2 X 10 - 3) 2.4 3.5 4.5 
A10m 
Cell volume (,...m3 X 10 - 4) 1. 4 2.4 5.1 
Cel l surface area (p.m2 x 10- 3) 2.8 4.1 6.6 
T he ceIl vo lume was calcu lated from scatter light at each phase with the usc of 
standard spherical beads. 
G2-M was 2.6-3.6 times greater and cell surface area of G2-M 
was 1. 9- 2.4 times grea ter than those of Gu/G ) on both cell lines 
(Table I) . There was a positive co rrelation between cell volume 
and cellular DNA content in AI 01D cells (Fig 1) . 
HLA-DR and P97 Levels During Cell Cycle Two-color 
analysis (HLA-DR or p97 vs DNA content) revealed that both 
HLA-DR and p97 levels increased as the cells progressed throug h 
Go/G ) to G2-M phase on both cell lines (Fig 2). Although 2 cell 
lines had different levels of FITC-flu orescence intensity, they ex-
pressed HLA-DR and p97 in a similar manner while moving 
th rough the cell cycle, as shown in Fig 2. 
Effects of Interferon on Cell Size, Cell Growth, and Cell 
Cycle In both melanoma cell lines y-interferon reduced cell 
volume from 82 to 95% as compared with non trea ted cells (Table 
II) . When melanoma cells were treated with various concentra-
tions (5-2000 IU / ml) of y-interferon, y-interferon induced dose-
dependent antiproliferative effects on both cell lines (Fig 3) . How-
ever, cell viability was not altered by the treatment (data not 
shown) . Even at the low concentration, 5 IU/ ml , y-interferon 
had an anti prolifera tive effect; A 101 D cells tended to be more 
susceptible to y-interferon than KHm-l/4 cells. In cell cycle anal-
ysis, 21% KHm-l/4 and 17% AlOlD cells were at Go/G ) phase 
without y-interferon treatment. After the treatment (500 IU/ml, 
72 h), cells accumulated at Go/G ), in KHm-l /4 37% and in AI 01D 
53% with a corresponding reduction in S to G2-M phase cells. 
This result indicates a decrease of cycling cells by y-interferon 
treatmen t (Table III) . 
Effects of Interferon on the Expression of HLA-DR and 
P97 KHm-1 /4 cells and Al01D cells ex pressed HLA-DR in 65% 
and 34%, respectively, without y-interferon treatment. After the 
Figure 1. Cellular DNA/cell volume histogram of AlOlD cells. The 
vertical axis shows the cell volume and the horizontal axis shows the 
cel lular ON A content as expressed by fluorescence intensity ofP) in linear 
units. 
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Figure 2. Cel lular DNA/FITC Auorescence histogram ofKHm-l /4 cells. 
The vertica l ax is shows the FITC-Auorcsccncc intensity in logarithmic 
units, the horizontal Jx is shows the PI-Auo rescence intensity in linear 
units. n, Sta ined with anti-HLA-DR monoclonal antibody. b, Stained 
with anti-p97 monoclona l antibody. 
treatment (500 IU /ml, 72 h), HLA-DR was expressed by 89% 
of the KHm-1 14 cells and 84% of the Al01D cells. As concerns 
p97 expression, 8% of the K Hm-1 /4 cells and 19% of the A101D 
cells expressed p97 before the treatm ent, and y-interferon in-
creased the expression of p97 on both cell li nes, to 12% of the 
KHm-1 /4 cells and 35% of the A10ID cell s. Gamma-interferon 
had no sign ifi cant effect on the fluorescence intensity in negative 
control cells (Fig 4). 
Effect of Interferon on HLA-DR and P97 Densities During 
Cell Cycle Gamma-interferon increased HLA-DR and p97 
densities in all cell cycle phases in both cell lines (Fig 5). After 
the treatment, HLA-DR density increased 1.62 times, p97 density 
increased 1.30 times in KHm-1I4, and 1.80 times and 1.62 times, 
respectively, in A 1010 w hen those densities were compared in 
the Go/G I phase. As observed in y-interferoll-nontreated cells, 
Table II. Effect of y-Interferon on Cell Volume 
Cell Line 
KHm-l/4 
A l OJO 
95 
85 
Cell Cycle Compartment 
s 
82 
90 
90 
93 
The cells were treated with 500 IU/ I11I of y-interferon for 3 days. Data were 
expressed as percent of cell vo lum e compared with ,),- intcrfcron nontrcatcd cells. 
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Figure 3. Antiproliferative effect of y-interferon. T he cells were treated 
with various concentrations (5-2000 IU / m l) of y-interferon for 6 days. 
Data are expressed as percent of contro l cells . (1)-(6) represents the con-
centration (IU/ ml) of y-interferon : (1) 5, (2) 10, (3) 50, (4) 100, (5) 500, 
and (6) 2000 rU/ ml, respectively. II, KHm-l /4. b, AIOID. 
the densities of those antigens remained relati vely constant, al-
though the densities tended to be lower in S phase as compared 
with those in GolG I and G2-M phases. 
D ISCUSSIO N 
Quantitative as well as qualitative heterogeneities have been ob-
served on melanoma tissues and melanoma cell lines [21,22,38-40J. 
Multiple lesions from a patient differed significantly in their reac-
tivity with a panel of monoclonal an tibodies [41 J. Antigenic het-
Table III. Effect of y-Interferon o n Cell Cycle 
Cell Cycle Compartment 
Cell Line GO/G1 S G2-M 
KHm-I /4 
Interferon( -) 21 59 20 
Intcrfcron( +) 37 49 14 
AlOlD 
In tcrferon( -) 17 55 28 
Interferon( + ) 53 41 6 
T he cells were treated with 500 IU / ml of y-inrerferoll for 3 days. Data arc ex-
pressed as percent o f cell numbers at cach cell cycle phase . 
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Figure 4. Histograms of A 1010 cells labeled with anti-HLA-DR or anti-
p97 monoclonal antibody plus FITC-conjugated goat antimollse immu-
noglobulin antibody. The vertical axes show the relative cell number per 
channel, the horizontal axes show the relative fluorescence intensity in 
logari thmic uni ts. T.he left curves are the negative controls, the middle 
curves are the nontreated cells, and the right curves arc the y-interferon-
treated cells. a, Stained with anti-HLA-DR monoclonal antibody. b, Stained 
with anti-p97 monoclonal antibody. 
erogcneity of clo nes and subclones fro m human m elanoma cell 
lines was dem onstrated by flow cyto m etric analysis [42] . T o ex-
plain this anti gen ic heterogeneity, several possibilities such as cell-
cycle related events [23,24], immuno logic m echanism s such as 
anti genic m odulat ion and immunoselecti on [43] have been sug-
ges ted . T he reason fo r this heterogeneity, however , is not under-
stood at th e present time. W e perform ed this study to solve the 
question. 
The impo rtant results o btained in the cell-cycle study are: (1) 
som e, bu t no t all m elano m a cell s expressed HLA-D R and p97; 
(2) the an tigen expressio ns were m aximall y observed at the 
Gz- M phase; bu t (3) the densities o f HLA-DR and p97 o n the cell 
surface were relatively constant throughout the cell cycle. These 
results dem o nstra ted that the di fferences in cell volume at each 
cell-cycle phase were related to the heterogeneity o f HLA-DR 
and p97 expressio n. T he express io n of MAA w as p reviously re-
po rted to be un iform througho ut the cell cycle [44]. O n the other 
hand, the expression of histocompatibility antigens and MAA 
was repo rted to change o n cultured human m elano m a cells during 
the cell cycle [23]. Our results agree with the latter study. The 
reason fo r this discrepancy m ay d epend upon different cell surface 
areas in the cell cycle as shown in our study , on the utilized cell 
lines, and o n the anti-MAA antibodies. 
y-lnterferon is assumed to play an important role in antitumor 
host reactions in mice and humans [45,46] and has been reported 
to induce o r increase the expressions of HLA-DR and MAA 
[1 7-19, 47] . The res ults obtained in this y-interferon study w ere 
that: (1) y-interferon increased HLA-DR and p97 expression on 
bo th cell lines; (2) y-interferon increased the densities of these 
antigens th roug hout cell cycle; (3) the increased densities w ere 
also relatively constant throug hout th e cell cycle as in no ntrea ted 
cells . AI 0ID melano m a cells were 34% HLA-DR + and 19% p97 + 
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Figure 5. HLA-DR and MAA densities during the cell cycle. The antigen 
density values were obtained by dividing the mean fluorescence intensity 
(representing the average antibody binding to surface antigens) by cell 
surface area at respective cell-cycle phases . These values of non treated 
cells at G, were set equal to 1. a, Nontreated KHm-1/4. b, Interferon-
treated KHm-1/4. c, Nontreated A101D. d, Interferion-treated AIOID. 
HLA-DR (solid line) and p97 (dashed line). Solid circie-Go/G, ; ope/! circle-S; 
square-Gz- M. 
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before y-interferon treatment, and HLA-DR + and p97 + cells in-
creased to 84% and 35%, respectively, after the treatment. Thus 
it was shown that the heterogeneity of antigen expression was 
strongly influenced by y-interferon . HLA-DR and p97 densities 
were increased approximately 1.1-1.8 times at each cell-cycle 
phase, but the densities were relatively constant during the cell 
cycle. These results may suggest that melanoma cells have nearly 
equal susceptibility to the treatment of y-interferon during dif-
ferent phases of the cell cycle. The results revealed that when 
y-interferon was incubated with melanoma cells, cell growth was 
inhibited dose-dependently and the cells accumulated at GO/G 1• 
This modulation of cell-cycle distribution m ay indirectly alter the 
expression of these 2 markers , and indicate a decrease of cycling 
cells, and thus the antiproliferative effects of y-interferon . y-In-
terferon has been shown to have a dose-dependent antiprolifer-
ative effect on a human melanoma cell line [20] and a-interferon 
has been reported to have an antiproliferative effect causing mod-
ulation of cell-cycle distribution, i.e., a-interferon hinders the 
transition of GO/G 1 cells into the cell cycle on human melanoma 
cells [48,49]. Again our results agree with these previous reports. 
In this study, the heterogeneity ofHLA-DR and p97 expression 
by human melanoma cells was confirmed and revealed to be 
influenced by the cell cycle, and by immunologic events such as 
y-interferon treatment. Further studies utilizing many other cell 
lines , antibodies, various interferons, and other immunomodu-
lators may elucidate other possible factors which influence anti-
genic heterogeneity in human melanoma and other malignant 
tumors . 
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